Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

elated to proprietary taste science technologies.  

Financial Review:The Company has modified the presentation of its statements of operations.  Historically, commercial revenues have been presented net of related direct costs, which to date have been comprised of royalty payments related to certain in-licensed technologies.  Effective with these 2012 financial results and for previous periods to which these results are compared, the related direct costs will be reported as a component of operating expenses defined as cost of commercial revenues.  This modification does not have an impact on cash flow or net results.  The financial results described below reflect this modification.

Total revenues were $31.3 million for 2012 compared to $31.6 million for 2011.  Total revenues were $8.2 million for the fourth quarter of 2012 compared to $8.6 million for the fourth quarter of 2011.

Development revenues were $27.0 million in 2012 compared to $28.2 million in 2011.  Development revenues were $6.7 million in the fourth quarter of 2012 compared to $7.7 million in the fourth quarter of 2011.  The decrease in the fourth quarter is primarily due to lower upfront license fee revenues recognized in 2012 compared to 2011.  Specifically, the Company recognized approximately $200,000 and $900,000 in the fourth quarter of 2012 and 2011, respectively, related to the $20 million in license payments under the 2009 Sweet Program collaboration with Firmenich.  There was no impact to cash flow as the license payments were received prior to 2011.

Commercial revenues were $4.3 million for 2012 compared to $3.4 million for 2011.  Commercial revenues were $1.5 million for the fourth quarter of 2012 compared to $940,000 for the fourth quarter of 2011. These increases resulted from higher commercial revenues related to our Savory Taste and Sweet Taste programs, as well as royalties from sales relat
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  ArroGen Group, an integrated advanced forensic solutions ... (FMID) technology Aug. 2-8 at the International Association ... Calif. FMID, a new ... agents, district attorneys and government agencies to build ... By analyzing chemical residues on fingerprints taken from ...
(Date:8/3/2015)... 3, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... th Annual Canaccord|Genuity Growth Conference in ... and CEO, William C. Taylor , President and ...
(Date:8/3/2015)... 3, 2015  Merck KGaA, Darmstadt, Germany ... high-tech products in the healthcare, life science and performance ... Nano-C, their development and launch of promising new fullerene ... Merck KGaA, Darmstadt, Germany , is ... sector. Novel derivatives: highly stable, easy to ...
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2
... , , , , , ... One,Medical, Inc. ("China Sky One Medical" or "the Company") ... developing and producing,over-the-counter drugs in the People,s Republic of ... that will be included in the 2009,Edition of the ...
... The Mosaic Company (NYSE: MOS ) plans to issue ... on Tuesday, January 5, 2010, after the close of trading on ... Mosaic,s website at mosaicco.com/investors. , The Company will host ... to discuss the results. The call will begin at 11:00 ...
... , , , , , , , ... - 45 Patients Enrolled in Study Designed to Evaluate the Ability ... Cardio3 BioSciences, a leading Belgian biotechnology company specialising,in cell-based therapies for ... months ahead of schedule,enrolment in the first stage of its pivotal ...
Cached Biology Technology:China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... 4, 2014) While adults make up 95 percent of ... study from the University of Colorado School of Medicine shows ... health concern. The study, published recently in the ... several important aspects of adult vaccination. Every year, 30,000 ...
... 2014 - A recent prospective study published in ... novel simplified laboratory method of culturing embryos suggested that ... system when compared with those reported by conventional IVF ... this new method. According to the results of this ...
... A UT Arlington bioengineer has received a four-year, $1.4 ... nanoparticle system to shore up arterial walls following angioplasty ... Nguyen, a UT Arlington associate professor of bioengineering, said ... angioplasty, which opens arteries and blood vessels that are ...
Cached Biology News:Thousands of unvaccinated adults die each year from preventable diseases 2First live births with a novel simplified IVF procedure 2UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls 2
... ( Abpromise for all tested applications). ... to amino acids 14/26 of Mouse Green cones ... acids 18/30 of tiger red cones opsin 1 ... Entrez Gene ID: 5956 ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Wnt-1 (G-19)...
Biology Products: